🇺🇸 DINUTUXIMAB BETA in United States

261 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 87 reports (33.33%)
  2. Pyrexia — 37 reports (14.18%)
  3. Pain — 24 reports (9.2%)
  4. Neoplasm Progression — 21 reports (8.05%)
  5. Death — 20 reports (7.66%)
  6. Therapy Partial Responder — 17 reports (6.51%)
  7. Device Related Infection — 16 reports (6.13%)
  8. Disease Progression — 16 reports (6.13%)
  9. Diarrhoea — 15 reports (5.75%)
  10. Pulmonary Toxicity — 8 reports (3.07%)

Source database →

DINUTUXIMAB BETA in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is DINUTUXIMAB BETA approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for DINUTUXIMAB BETA in United States?

Marketing authorisation holder not available in our data.